Essential Thrombocythemia - Pipeline Review, H1 2018

  • ID: 4518501
  • Drug Pipelines
  • 83 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp
  • MORE
Essential Thrombocythemia - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2018, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.

Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.

Report Highlights:

This latest pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 3, 4 and 2 respectively.

Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp
  • MORE
Introduction

Report Coverage

Essential Thrombocythemia - Overview

Essential Thrombocythemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Essential Thrombocythemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Essential Thrombocythemia - Companies Involved in Therapeutics Development

AbbVie Inc

Aop Orphan Pharmaceuticals AG

F. Hoffmann-La Roche Ltd

Incyte Corp

Italfarmaco SpA

MEI Pharma Inc

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Essential Thrombocythemia - Drug Profiles

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anagrelide hydrochloride PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Essential Thrombocythemia - Dormant Projects

Essential Thrombocythemia - Discontinued Products

Essential Thrombocythemia - Product Development Milestones

Featured News & Press Releases

Nov 15, 2017: Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) for the Treatment of Essential Thrombocythemia

Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting

Dec 28, 2016: Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)

Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

Jun 13, 2016: Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress

Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance

Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting

May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Essential Thrombocythemia, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Essential Thrombocythemia - Pipeline by AbbVie Inc, H1 2018

Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H1 2018

Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Essential Thrombocythemia - Pipeline by Incyte Corp, H1 2018

Essential Thrombocythemia - Pipeline by Italfarmaco SpA, H1 2018

Essential Thrombocythemia - Pipeline by MEI Pharma Inc, H1 2018

Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, H1 2018

Essential Thrombocythemia - Pipeline by SELLAS Life Sciences Group Inc, H1 2018

Essential Thrombocythemia - Dormant Projects, H1 2018

Essential Thrombocythemia - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Essential Thrombocythemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Aop Orphan Pharmaceuticals AG
  • F. Hoffmann-La Roche Ltd
  • Incyte Corp
  • Italfarmaco SpA
  • MEI Pharma Inc
  • PharmaEssentia Corp
  • SELLAS Life Sciences Group Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll